{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T18:27:30Z","timestamp":1787509650192,"version":"build-2736575974"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2020,4,18]],"date-time":"2020-04-18T00:00:00Z","timestamp":1587168000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,4,18]],"date-time":"2020-04-18T00:00:00Z","timestamp":1587168000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Bone Marrow Transplant"],"published-print":{"date-parts":[[2020,8]]},"DOI":"10.1038\/s41409-020-0892-7","type":"journal-article","created":{"date-parts":[[2020,4,18]],"date-time":"2020-04-18T15:02:48Z","timestamp":1587222168000},"page":"1525-1532","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["CAR T-cell therapy for the management of refractory\/relapsed high-grade B-cell lymphoma: a practical overview"],"prefix":"10.1038","volume":"55","author":[{"given":"Mohamad","family":"Mohty","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Remy","family":"Dulery","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5769-8409","authenticated-orcid":false,"given":"Jordan","family":"Gauthier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3474-0002","authenticated-orcid":false,"given":"Florent","family":"Malard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eolia","family":"Brissot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahmoud","family":"Aljurf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Bazarbachi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3755-4889","authenticated-orcid":false,"given":"Christian","family":"Chabanon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7394-5185","authenticated-orcid":false,"given":"Mohamed A.","family":"Kharfan-Dabaja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bipin N.","family":"Savani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"He","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saad S.","family":"Kenderian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel-Angel","family":"Perales","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ibrahim","family":"Yakoub-Agha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnon","family":"Nagler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,4,18]]},"reference":[{"key":"892_CR1","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/S1470-2045(08)70002-0","volume":"9","author":"M Pfreundschuh","year":"2008","unstructured":"Pfreundschuh M, Schubert J, Ziepert M, Schmits R, Mohren M, Lengfelder E, et al. Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60). Lancet Oncol. 2008;9:105\u201316.","journal-title":"Lancet Oncol"},{"key":"892_CR2","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1016\/S1470-2045(11)70235-2","volume":"12","author":"M Pfreundschuh","year":"2011","unstructured":"Pfreundschuh M, Kuhnt E, Trumper L, Osterborg A, Trneny M, Shepherd L, et al. CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group. Lancet Oncol. 2011;12:1013\u201322.","journal-title":"Lancet Oncol"},{"key":"892_CR3","doi-asserted-by":"publisher","first-page":"1250","DOI":"10.1016\/S1470-2045(12)70481-3","volume":"13","author":"N Schmitz","year":"2012","unstructured":"Schmitz N, Nickelsen M, Ziepert M, Haenel M, Borchmann P, Schmidt C, et al. Conventional chemotherapy (CHOEP-14) with rituximab or high-dose chemotherapy (MegaCHOEP) with rituximab for young, high-risk patients with aggressive B-cell lymphoma: an open-label, randomised, phase 3 trial (DSHNHL 2002-1). Lancet Oncol. 2012;13:1250\u20139.","journal-title":"Lancet Oncol"},{"key":"892_CR4","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1182\/asheducation-2011.1.498","volume":"2011","author":"JW Friedberg","year":"2011","unstructured":"Friedberg JW. Relapsed\/refractory diffuse large B-cell lymphoma. Hematol Am Soc Hematol Educ Program. 2011;2011:498\u2013505.","journal-title":"Hematol Am Soc Hematol Educ Program"},{"key":"892_CR5","doi-asserted-by":"publisher","first-page":"196","DOI":"10.6004\/jnccn.2016.0023","volume":"14","author":"AD Zelenetz","year":"2016","unstructured":"Zelenetz AD, Gordon LI, Wierda WG, Abramson JS, Advani RH, Andreadis CB, et al. Diffuse large B-cell lymphoma version 1.2016. J Natl Compr Canc Netw. 2016;14:196\u2013231.","journal-title":"J Natl Compr Canc Netw"},{"key":"892_CR6","doi-asserted-by":"publisher","first-page":"1800","DOI":"10.1182\/blood-2017-03-769620","volume":"130","author":"M Crump","year":"2017","unstructured":"Crump M, Neelapu SS, Farooq U, Van Den Neste E, Kuruvilla J, Westin J, et al. Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study. Blood. 2017;130:1800\u20138.","journal-title":"Blood"},{"key":"892_CR7","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1016\/j.bbmt.2006.12.452","volume":"13","author":"RE Lerner","year":"2007","unstructured":"Lerner RE, Thomas W, Defor TE, Weisdorf DJ, Burns LJ. The International Prognostic Index assessed at relapse predicts outcomes of autologous transplantation for diffuse large-cell non-Hodgkin\u2019s lymphoma in second complete or partial remission. Biol Blood Marrow Transplant. 2007;13:486\u201392.","journal-title":"Biol Blood Marrow Transplant"},{"key":"892_CR8","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1002\/cncr.32526","volume":"126","author":"EC Ayers","year":"2019","unstructured":"Ayers EC, Li S, Medeiros LJ, Bond DA, Maddocks KJ, Torka P. et al. Outcomes in patients with aggressive B-cell non-Hodgkin lymphoma after intensive frontline treatment failure. Cancer. 2019;126:293\u2013303.","journal-title":"Cancer"},{"key":"892_CR9","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1002\/ajh.23524","volume":"88","author":"SJ Nagle","year":"2013","unstructured":"Nagle SJ, Woo K, Schuster SJ, Nasta SD, Stadtmauer E, Mick R, et al. Outcomes of patients with relapsed\/refractory diffuse large B-cell lymphoma with progression of lymphoma after autologous stem cell transplantation in the rituximab era. Am J Hematol. 2013;88:890\u20134.","journal-title":"Am J Hematol"},{"key":"892_CR10","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.retram.2018.03.005","volume":"66","author":"A Ghobadi","year":"2018","unstructured":"Ghobadi A. Chimeric antigen receptor T cell therapy for non-Hodgkin lymphoma. Curr Res Transl Med. 2018;66:43\u20139.","journal-title":"Curr Res Transl Med"},{"key":"892_CR11","doi-asserted-by":"publisher","first-page":"4017","DOI":"10.1182\/blood-2014-12-580068","volume":"125","author":"SL Maude","year":"2015","unstructured":"Maude SL, Teachey DT, Porter DL, Grupp SA. CD19-targeted chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia. Blood. 2015;125:4017\u201323.","journal-title":"Blood"},{"key":"892_CR12","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1038\/nbt.2725","volume":"31","author":"CS Hinrichs","year":"2013","unstructured":"Hinrichs CS, Restifo NP. Reassessing target antigens for adoptive T-cell therapy. Nat Biotechnol. 2013;31:999\u20131008.","journal-title":"Nat Biotechnol"},{"key":"892_CR13","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.retram.2017.08.003","volume":"65","author":"J Gauthier","year":"2017","unstructured":"Gauthier J, Yakoub-Agha I. Chimeric antigen-receptor T-cell therapy for hematological malignancies and solid tumors: clinical data to date, current limitations and perspectives. Curr Res Transl Med. 2017;65:93\u2013102.","journal-title":"Curr Res Transl Med"},{"key":"892_CR14","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.retram.2018.03.004","volume":"66","author":"S Grupp","year":"2018","unstructured":"Grupp S. Beginning the CAR T cell therapy revolution in the US and EU. Curr Res Transl Med. 2018;66:62\u20134.","journal-title":"Curr Res Transl Med"},{"key":"892_CR15","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1007\/s11899-016-0336-z","volume":"11","author":"M Ruella","year":"2016","unstructured":"Ruella M, June CH. Chimeric antigen receptor T cells for B cell neoplasms: choose the right CAR for you. Curr Hematol Malig Rep. 2016;11:368\u201384.","journal-title":"Curr Hematol Malig Rep"},{"key":"892_CR16","doi-asserted-by":"publisher","first-page":"7505","DOI":"10.1200\/JCO.2018.36.15_suppl.7505","volume":"36","author":"JS Abramson","year":"2018","unstructured":"Abramson JS, Gordon LI, Palomba ML, Lunning MA, Arnason JE, Forero-Torres A, et al. Updated safety and long term clinical outcomes in TRANSCEND NHL 001, pivotal trial of lisocabtagene maraleucel (JCAR017) in R\/R aggressive NHL. J Clin Oncol. 2018;36:7505\u20137505.","journal-title":"J Clin Oncol"},{"key":"892_CR17","doi-asserted-by":"publisher","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","volume":"377","author":"SS Neelapu","year":"2017","unstructured":"Neelapu SS, Locke FL, Bartlett NL, Lekakis LJ, Miklos DB, Jacobson CA, et al. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N Engl J Med. 2017;377:2531\u201344.","journal-title":"N Engl J Med"},{"key":"892_CR18","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1056\/NEJMoa1804980","volume":"380","author":"SJ Schuster","year":"2019","unstructured":"Schuster SJ, Bishop MR, Tam CS, Waller EK, Borchmann P, McGuirk JP, et al. Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma. N Engl J Med. 2019;380:45\u201356.","journal-title":"N Engl J Med"},{"key":"892_CR19","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1182\/blood-2018-99-114152","volume":"132","author":"LJ Nastoupil","year":"2018","unstructured":"Nastoupil LJ, Jain MD, Spiegel JY, Ghobadi A, Lin Y, Dahiya S, et al. Axicabtagene ciloleucel (Axi-cel) CD19 chimeric antigen receptor (CAR) T-cell therapy for relapsed\/refractory large B-cell lymphoma: real world experience. Blood. 2018;132:91\u201391.","journal-title":"Blood"},{"key":"892_CR20","doi-asserted-by":"publisher","first-page":"S41","DOI":"10.1016\/j.bbmt.2019.12.108","volume":"26","author":"PA Riedell","year":"2020","unstructured":"Riedell PA, Walling C, Nastoupil LJ, Pennisi M, Maziarz RT, McGuirk JP, et al. A multicenter retrospective analysis of outcomes and toxicities with commercial axicabtagene ciloleucel and tisagenlecleucel for relapsed\/refractory aggressive B-cell lymphomas. Biol Blood Marrow Transplant. 2020;26:S41\u20132.","journal-title":"Biol Blood Marrow Transplant"},{"key":"892_CR21","doi-asserted-by":"publisher","first-page":"297","DOI":"10.3324\/haematol.2019.229781","volume":"105","author":"I Yakoub-Agha","year":"2019","unstructured":"Yakoub-Agha I, Chabannon C, Bader P, Basak GW, Bonig H, Ciceri F. et al. Management of adults and children undergoing CAR T-cell therapy: best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE). Haematologica. 2019;105:297\u2013316.","journal-title":"Haematologica"},{"key":"892_CR22","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1002\/hon.110_2630","volume":"37","author":"C Thieblemont","year":"2019","unstructured":"Thieblemont C, Le Gouill S, Di Blasi R, Cartron G, Morschhauser F, Bachy E, et al. Real-world results on CD19 CAR T-cell for 60 French patients with relapsed\/refractory diffuse large B-cell lymphoma included in a temporary authorization for use program. Hematological Oncol. 2019;37:301\u2013301.","journal-title":"Hematological Oncol"},{"key":"892_CR23","doi-asserted-by":"crossref","unstructured":"Frigault MJ, Dietrich J, Martinez-Lage M, Leick M, Choi BD, DeFilipp Z. et al. Tisagenlecleucel CAR-T cell therapy in secondary CNS lymphoma. Blood. 2019;134:860\u20136.","DOI":"10.1182\/blood.2019001694"},{"key":"892_CR24","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1182\/blood-2019-129097","volume":"134","author":"NN Bennani","year":"2019","unstructured":"Bennani NN, Maurer MJ, Nastoupil LJ, Jain MD, Chavez JC, Cashen AF, et al. Experience with axicabtagene ciloleucel (Axi-cel) in patients with secondary CNS involvement: results from the US lymphoma CAR T consortium. Blood. 2019;134:763\u2013763.","journal-title":"Blood"},{"key":"892_CR25","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1182\/blood.2019001694","volume":"134","author":"MJ Frigault","year":"2019","unstructured":"Frigault MJ, Dietrich J, Martinez-Lage M, Leick M, Choi BD, DeFilipp Z, et al. Tisagenlecleucel CAR T-cell therapy in secondary CNS lymphoma. Blood. 2019;134:860\u20136.","journal-title":"Blood"},{"key":"892_CR26","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.1016\/j.ijrobp.2019.05.065","volume":"105","author":"AJ Sim","year":"2019","unstructured":"Sim AJ, Jain MD, Figura NB, Chavez JC, Shah BD, Khimani F, et al. Radiation therapy as a bridging strategy for CAR T cell therapy with axicabtagene ciloleucel in diffuse large B-cell lymphoma. Int J Radiat Oncol. 2019;105:1012\u201321.","journal-title":"Int J Radiat Oncol"},{"key":"892_CR27","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/j.ymthe.2016.10.020","volume":"25","author":"FL Locke","year":"2017","unstructured":"Locke FL, Neelapu SS, Bartlett NL, Siddiqi T, Chavez JC, Hosing CM, et al. Phase 1 results of ZUMA-1: a multicenter study of KTE-C19 anti-CD19 CAR T cell therapy in refractory aggressive lymphoma. Mol Ther. 2017;25:285\u201395.","journal-title":"Mol Ther"},{"key":"892_CR28","doi-asserted-by":"publisher","first-page":"1803","DOI":"10.1200\/JCO.2016.71.3024","volume":"35","author":"JN Kochenderfer","year":"2017","unstructured":"Kochenderfer JN, Somerville RPT, Lu T, Shi V, Bot A, Rossi J, et al. Lymphoma remissions caused by anti-CD19 chimeric antigen receptor T cells are associated with high serum interleukin-15 levels. J Clin Oncol. 2017;35:1803\u201313.","journal-title":"J Clin Oncol"},{"key":"892_CR29","doi-asserted-by":"crossref","unstructured":"Turtle CJ, Hanafi L-AA, Berger C, Hudecek M, Pender B, Robinson E. et al. Immunotherapy of non-Hodgkin\u2019s lymphoma with a defined ratio of CD8+ and CD4+ CD19-specific chimeric antigen receptor-modified T cells. Sci Transl Med. 2016;8:355ra116.","DOI":"10.1126\/scitranslmed.aaf8621"},{"key":"892_CR30","doi-asserted-by":"crossref","unstructured":"Turtle CJ, Hay KA, Hanafi L-A, Li D, Cherian S, Chen X. et al. Durable molecular remissions in chronic lymphocytic leukemia treated with CD19-specific chimeric antigen receptor\u2013modified T cells after failure of ibrutinib. J Clin Oncol. 2017;35:3010\u201320.","DOI":"10.1200\/JCO.2017.72.8519"},{"key":"892_CR31","doi-asserted-by":"publisher","first-page":"1799","DOI":"10.1182\/blood-2019-03-900928","volume":"133","author":"SS Neelapu","year":"2019","unstructured":"Neelapu SS. CAR-T efficacy: is conditioning the key? Blood. 2019;133:1799\u20131800.","journal-title":"Blood"},{"key":"892_CR32","doi-asserted-by":"publisher","first-page":"3321","DOI":"10.1182\/blood-2016-04-703751","volume":"127","author":"JN Brudno","year":"2016","unstructured":"Brudno JN, Kochenderfer JN. Toxicities of chimeric antigen receptor T cells: recognition and management. Blood. 2016;127:3321\u201330.","journal-title":"Blood"},{"key":"892_CR33","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.retram.2018.03.003","volume":"66","author":"J Gauthier","year":"2018","unstructured":"Gauthier J, Turtle CJ. Insights into cytokine release syndrome and neurotoxicity after CD19-specific CAR-T cell therapy. Curr Res Transl Med. 2018;66:50\u20132.","journal-title":"Curr Res Transl Med"},{"key":"892_CR34","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/nrclinonc.2017.148","volume":"15","author":"SS Neelapu","year":"2018","unstructured":"Neelapu SS, Tummala S, Kebriaei P, Wierda W, Gutierrez C, Locke FL, et al. Chimeric antigen receptor T-cell therapy\u2014assessment and management of toxicities. Nat Rev Clin Oncol. 2018;15:47\u201362.","journal-title":"Nat Rev Clin Oncol"},{"key":"892_CR35","unstructured":"Novartis Pharmaceuticals Corporation. Kymriah\u00ae [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2017."},{"key":"892_CR36","volume-title":"Committee for advanced therapies: guideline on the quality, non\u00adclinical and clinical aspects of gene therapy medicinal products","author":"EMA.","year":"2018","unstructured":"EMA. Committee for advanced therapies: guideline on the quality, non\u00adclinical and clinical aspects of gene therapy medicinal products. Amsterdam: European Medicines Agency; 2018."},{"key":"892_CR37","volume-title":"Testing of retroviral vector-based human gene therapy products for replication competent retrovirus during product manufacture and patient follow-up (final guidance document)","author":"US FDA.","year":"2020","unstructured":"US FDA. Testing of retroviral vector-based human gene therapy products for replication competent retrovirus during product manufacture and patient follow-up (final guidance document). White Oak, MD: Food and Drug Administration; 2020."}],"container-title":["Bone Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41409-020-0892-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41409-020-0892-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41409-020-0892-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T17:18:08Z","timestamp":1684603088000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41409-020-0892-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,18]]},"references-count":37,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2020,8]]}},"alternative-id":["892"],"URL":"https:\/\/doi.org\/10.1038\/s41409-020-0892-7","relation":{},"ISSN":["0268-3369","1476-5365"],"issn-type":[{"value":"0268-3369","type":"print"},{"value":"1476-5365","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,4,18]]},"assertion":[{"value":"10 March 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 March 2020","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 March 2020","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 April 2020","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"MM reports grants and\/or lecture honoraria from Janssen, Sanofi, Maat Pharma, JAZZ pharmaceutical, Celgene, Amgen, BMS, Takeda, Pfizer, and Roche, all outside the submitted work. FM reports lecture honoraria from Therakos\/Mallinckrodt, Biocodex, Janssen, Keocyte, Sanofi, JAZZ pharmaceutical and Astellas, all outside the submitted work. AB reports honoraria from Abbvie, Novartis, Takeda, Roche, Celgene, Pfizer, Janssen and Amgen and Research support from Novartis, Takeda, Roche, Celgene and Janssen. CC reports honoraria from Kite\/Gilead and Novartis. SSK is inventor on patents and royalties licensed to Novartis, Humanigen, and Mettaforge. He receives research support from Kite, Gilead, Novartis, Juno, Celgene, Humanigen, Tolero, Lentigen, Sunesis, and Morphosys. He has served on SAB for Humanigen, Kite, and Juno. M-AP reports honoraria from Abbvie, Bellicum, Bristol-Myers Squibb, Celgene, Incyte, Merck, Novartis, Nektar Therapeutics, Omeros, and Takeda. He serves on DSMBs for Servier and Medigene, and the scientific advisory boards of MolMed and NexImmune. He has received research support for clinical trials from Incyte, Kite (Gilead) and Miltenyi. IY-A reports honorarium from Gilead\/Kite, Celgene, Novartis and Jansse. The other authors did not disclose any relevant conflict of interest in relation to this work","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}